ArticleEJNMMI research2020
Inter- and intraobserver agreement of the quantitative assessment of [
Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of Programmed Death Ligand-1 Expression in Non-small Cell Lung Cancer
A Single-arm, Phase II Study to Evaluate PD-L1 Expression in Non-Small Cell Lung Cancer Using the 99mTc Labelled Anti-PD-L1 Single Domain Antibody (NM-01)
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Article
- Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer.International journal of nanomedicine · 2023Article
- Retraction Note to: Inter- and intraobserver agreement of the quantitative assessment of [EJNMMI research · 2021Article
- Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic.Frontiers in oncology · 2021Review
Corrections and comments
- Retraction · 2021-10-12Copyright Claims · Lack of Approval from Third Party ·
- Retracted
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
purposeCheckpoint inhibition therapy using monoclonal antibodies against programmed cell death protein 1 (PD-1) or its ligand (PD-L1) is now standard management of non-small cell lung cancer (NSCLC). PD-L1 expression is a validated and approved prognostic and predictive biomarker for anti-PD-1/PD-L1 therapy. Technetium-99 m [
methods[
resultsIntraclass correlation of primary lung tumour-to-blood pool (T:BP; ICC 0.83, 95% CI 0.73-0.90) and lymph node metastasis-to-blood pool (LN:BP; ICC 0.87, 0.81-0.92) measures of [
conclusionGood to excellent inter- and intraobserver agreement of the quantitative assessment of [ CLINICAL
trial registrationClinicalTrials.gov identifier no. NCT02978196. Registered 30th November 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.